PPARA and Insulin resistance: Pioglitazone, a peroxisome proliferator-activated receptor (PPAR) agonist, is a glucose-lowering agent that reduces insulin resistance in the liver, muscle and adipose tissue and increases lipid storage in the subcutaneous adipose tissue, also improving the serum lipid profile.